(Alliance News) - Diaceutics PLC on Monday it will deliver customised data insights to a "top five global" pharmaceutical firm under a new contract.
Under the three-year contract, worth just over USD2 million, the Belfast-based testing laboratories company "will provide comprehensive mapping and analysis of US physicians and labs who perform testing for non-small cell lung cancer", it explained.
Diaceutics will correlate labs to corresponding physician testing behaviours, it added. Diaceutics has been working with the pharmaceutical firm, which it didn't name, since 2014.
The data insight will be delivered via the company's diagnostic commercialisation platform DXRX. This integrates "multiple pipelines of real-world diagnostic testing data from a global network of laboratories", Diaceutics explains on its website.
"As the treatment of cancer has become progressively more biomarker-driven, and with the rapid emergence of effective matched targeted therapies, pharma companies are making attempts to define best practices for which tests are necessary and in what target population. The DXRX intelligence will be a vital tool in enabling our customer to achieve this and optimising their sales territories," Chief Commercial Officer Jordan Clark said Monday.
Diaceutics shares were 3.7% higher at 106.80 pence each in London on Monday morning.
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Diaceutics (DXRX)